期刊文献+

卵巢囊肿超声诊断及临床应用价值 被引量:1

下载PDF
导出
摘要 目的:探讨超声技术在临床中诊断卵巢囊肿的应用价值。方法:选取2017年2月至2017年8月本院收治的卵巢囊肿患者49例,根据患者的声像图特征与临床表现分为两组,对照组患者不接受手术,研究组患者接受手术,并且对研究组的超声诊断和术后病理诊断进行比较。结果:研究组患者的卵巢囊肿与对照组相比在囊肿大小、囊内透声性以及内部回声的差异具有统计学意义(P<0.05),卵巢囊肿的超声诊断与术后的病理诊断符合率高达86.95%。结论:在卵巢囊肿的诊断过程当中,超声诊断的效果理想,临床上可进一步推广应用。
出处 《中外女性健康研究》 2018年第3期43-43,46,共2页 Women's Health Research
  • 相关文献

参考文献4

二级参考文献30

  • 1程静新,刘诚明,李庭芳,李莉.复发性上皮性卵巢癌二线化疗的回顾性分析[J].中国妇产科临床杂志,2004,5(3):189-191. 被引量:2
  • 2王永莉,张书予,闫媛媛,王蓓蓓.超声对卵巢血肿的鉴别诊断[J].中国超声诊断杂志,2005,6(10):760-762. 被引量:5
  • 3金姣.卵巢囊肿39例超声诊断与病理结果对照分析[J].中国误诊学杂志,2008,8(1):193-194. 被引量:2
  • 4Eisenhauer EA,Therasse P,Bogaerts J, et al. New response e- valuation criteria in solid tumours: revised RECIST guideline (version 1.1) [J].EurJ Cancer,2009,45(2):228-247. 被引量:1
  • 5Trotti A, Colevas AD,Setser A,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treat- ment[J]. Semin Radiat Oncol,2003, 13(3): 176-181. 被引量:1
  • 6Matsumoto K,Katsumata N,Shibata T, et al. Phase Ⅱ trial of oral etoposide plus intravenous irinotecan in patients with plati- num-resistant and taxane-pretreated ovarian cancer (JCOG0503) [J]. Gynecol Oncol, 2015,136(2) : 218-223. 被引量:1
  • 7Tomao F, Tomao S,Benedetti Panici P, et al. Combination of bev- acizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial[J]. J Clin On- coi,2014,32(31) :3580. 被引量:1
  • 8Safra T,Asna N,Veizman A, et al. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum- resistant and platinum-sensitive recurrent epithelial ovarian cancer pa- tients[J]. Anticanccr Drugs,2014,25(3) :340-345. 被引量:1
  • 9Vergote I, Schilder RJ,Pippitt CH Jr, et al. A phase lb study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or par- tially platinum-sensitive ovarian cancer[J]. Gynecol Oncol, 2014, 135(1) :25-33. 被引量:1
  • 10Hong SH, Lee S,Kim HG,et al. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary perito- neal cancer by the Korean Cancer Study Group (KCSG)_KCSG GYI0-10[J]. Gynecol Oneoi,2015,136(2) :212-217. 被引量:1

共引文献74

同被引文献14

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部